ABIVAX Société Anonyme (ABVX)

Market Cap	6.96B
Revenue (ttm)	7.07M
Net Income (ttm)	-229.46M
Shares Out	63.47M
EPS (ttm)	-3.63
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	523,454
Open	90.81
Previous Close	90.71
Day's Range	90.00 - 92.20
52-Week Range	4.77 - 98.64
Beta	0.10
Analysts	Strong Buy
Price Target	103.80 (+14.73%)
Earnings Date	Aug 11, 2025

About ABVX

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 69
• Stock Exchange: NASDAQ
• Ticker Symbol: ABVX
• Website: https://www.abivax.com

Financial Performance

In 2024, ABIVAX Société Anonyme's revenue was 10.79 million, an increase of 135.94% compared to the previous year's 4.57 million. Losses were -176.24 million, 19.3% more than in 2023.

Financial numbers in EUR

Analyst Summary

According to 10 analysts, the average rating for ABVX stock is "Strong Buy." The 12-month stock price target is $103.8, which is an increase of 14.73% from the latest price.

Price Target

$103.8

(14.73% upside)

Analyst Consensus: Strong Buy